Results
eNauka >
Rezultati >
A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A(3) adenosine receptor agonist (A(3)AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).
| Naziv: | A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A(3) adenosine receptor agonist (A(3)AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC). | Autori  : | Stemmer, Salomon M; Manojlovic, Nebojsa S   ; ...; Natosevic, Sladjana; ...; (broj, koautora 20) |
Godina: | 2019 | Publikacija: | JOURNAL OF CLINICAL ONCOLOGY | ISSN: | 0732-183X e1527-7755 Journal of Clinical Oncology Pretraži identifikator |
Izdavač: | American Society of Clinical Oncology | Tip rezultata: | Konferencijski rad | Kolacija: | vol. 37 br. 15 Suppl. (Meeting Abstract 2503) | DOI: | 10.1200/JCO.2019.37.15_suppl.2503 | WoS-ID: | 000487345804455 | URI: | https://enauka.gov.rs/handle/123456789/937115 | URL: | https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.2503 | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.